Glucosylated heparin derivatives as non-toxic anti-cancer drugs

Journal of Controlled Release

Volumn 123, Issue 1, 2007, Pages 46-55

  Lee, Gee Young ^a   Kim, Sang Kyoon ^a   Byun, Youngro ^b  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Anti cancer drug; Glucosylated heparin; GLUTs; Heparin; LMWH

Indexed keywords

COAGULATION; GLUCOSE; MOLECULAR WEIGHT; ONCOLOGY; TOXICITY;

ANTI-CANCER DRUG; GLUCOSE TRANSPORTERS (GLUT); GLUCOSYLATED HEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN (LMWH);

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; GLUCOSAMINE; GLUCOSE DERIVATIVE; HEPARIN DERIVATIVE;

ANTICOAGULATION; ARTICLE; CANCER INHIBITION; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; DRUG FORMULATION; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; HEPARIN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; NEOPLASMS;

EID: 34548845307     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.07.017     Document Type: Article

References (41)

1. Iozzo R.V., and San Antonio J.D. Heparan sulfate proteolycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108 (2001) 349-355
2. Jiang X., and Couchman J.R. Perlecan and tumor angiogenesis. J. Histochem. Cytochem. 51 (2003) 1393-1410
3. Blackhall F.H., Merry C.L., Davies E.J., and Jayson G.C. Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85 (2001) 1094-1098
4. Sanderson R.D. Heparan sulfate proteoglycans in invasion and metastasis. Semin. Cell Dev. Biol. 12 (2001) 89-98
5. Stringer S.E./. The role of heparan sulphate proteoglycans in angiogenesis. Biochem. Soc. Trans. 34 (2006) 451-453
6. Sasisekharan R., Shriver Z., Venkataraman G., and Narayanasami U. Roles of heparan-sulphate glyscosaminoglycans in cancer. Nat. Rev., Cancer 2 (2002) 521-528
7. Zacharski L.R., Ornstein D.L., and Mamourian A.C. Lowmolecular-weight heparin and cancer. Semin. Thromb. Hemost. 26 (2000) 69-77
8. Kanematsu A., Marui A., Yamamoto S., Ozeki M., Hirano Y., Yamamoto M., Ogawa O., Komeda M., and Tabata Y. Type I collagen can function as a reservoir of basic fibroblast growth factor. J. Control. Release 99 (2004) 281-292
9. Smorenburg S.M., and Van Noorden C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 53 (2001) 93-105
10. Lee K.Y., Peters M.C., and Mooney D.J. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J. Control. Release 87 (2003) 49-56
11. Lapierre F., Holme K., Lam L., Tressler R.J., Storm N., Wee J., Stack R.J., Castellot J., and Tyrrell D.J. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6 (1996) 355-366
12. Wei M., Tai G., Gao Y., Li N., Huang B., Zhou Y., Hao S., and Zeng X. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J. Biol. Chem. 279 (2004) 29202-29210
13. Casu B., Guerrini M., Guglieri S., Naggi A., Perez M., Torri G., Cassinelli G., Ribatti D., Carminati P., Giannini G., Penco S., Pisano C., Belleri M., Rusnati M., and Presta M. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J. Med. Chem. 47 (2004) 838-848
14. Gao Y., Wei M., Zheng S., Ba X., Hao S., and Zeng X. Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. J. Cancer Res. Clin. Oncol. 132 (2006) 257-264
15. Park K., Lee G.Y., Kim Y., Yu M., Park R., Kim I., Kim S.Y., and Byun Y. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J. Control. Release 114 (2006) 300-306
16. Kim S.K., Lee D.Y., Lee E., Lee Y.-k., Kim C.Y., Moon H.T., and Byun Y. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J. Control. Release 120 (2007) 4-10
17. Lee D.Y., Kim S.K., Kim Y.S., Son D.H., Nam J.H., Kim I.S., Park R.W., Kim S.Y., and Byun Y. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. J. Control. Release 118 (2007) 310-317
18. Park K., Kim Y., Lee G.Y., Nam J., Lee S.K., Park R., Kim S.Y., Kim I., and Byun Y. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm. Res. 24 (2007) 176-185
19. Yu M.K., Lee D.Y., Kim Y., Park K., Park S.A., Son D.H., Lee G.Y., Nam J.H., Kim S.Y., Kim I., Park R., and Byun Y. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm. Res. 24 (2007) 705-714
20. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
21. Weber G. Enzymology of cancer cells. N. Engl. J. Med. 296 (1977) 541-551
22. Yamamoto T., Seino Y., Fukumono H., Koh G., Yano H., Inagaki N., Yamada Y., Inoune K., Manabe T., and Imura H. Over expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun. 170 (1990) 223-230
23. Younes M., Lechago L., Somoano J., Mosharaf M., and Lechago J. Wide distribution of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res. 56 (1996) 1164-1167
24. Medina R.A., and Owen G.I. Glucose transporters: expression, regulation and cancer. Biol. Res. 35 (2002) 9-26
25. Brown R., and Wahl R. Over-expression of Glut 1 glucose transporter in human breast cancer: an immunohistochemistry study. Cancer 15 (1993) 2979-2985
26. Younes M., Brown R.W., Mody D.R., Fernandez L., and Laucirica R. Glut 1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15 (1995) 2895-2898
27. Macheda M.L., Rogers S., and Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202 (2005) 654-662
28. Godoy A., Ulloa V., Rodríguez F., Reinicke K., Yañez A.J., GarcíA MDe.L., Medina R.A., Carrasco M., Barberis S., Castro T., Martínez F., Koch X., Vera J.C., Poblete M.T., Figueroa C.D., Peruzzo B., Pérez F., and Nualart F. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J. Cell. Physiol. 207 (2006) 614-627
29. Bentley J., Walker I., McIntosh E., Whetton A., Owen-Lynch P., and Baldwin S. Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid Leukemia model. Br. J. Haematol. 112 (2001) 212-215
30. Greiner E., Guppy M., and Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J. Biol. Chem. 269 (1994) 31482-31490
31. Kan O., Baldwin S.A., and Whetton A.D. Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line. J. Exp. Med. 180 (1994) 917-923
32. Vander Heiden M.C., Plas D.R., Rathmell J.C., Fox C.J., Harris M.H., and Thompson C.B. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell Biol. 21 (2001) 5899-5912
33. Di Chiro G., DeLaPaz R.L., Brooks R.A., Sokoloff L., Kornblith P.L., Smith B.H., Patronas N.J., Kufta C.V., Kessler R.M., Johnston G.S., Manning R.G., and Wolf A.P. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32 (1982) 1323-1329
34. Oshida M., Uno K., Suzuki M., Nagashima T., Hashimoto H., Yagata H., Shishikura T., Imazeki K., and Nakajima N. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 82 (1998) 2227-2234
35. Schwarzbach M.H., Dimitrakopoulou-Strauss A., Willeke F., Hinz U., Strauss L.G., Zhang Y.M., Mechtersheimer G., Attigah N., Lehnert T., and Herfarth C. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg. 231 (2000) 380-386
36. Seker H., Bertram B., Burkle A., Kaina B., Pohl J., Koepsell H., and Wiesser M. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br. J. Cancer 82 (2000) 629-634
37. Briasoulis E., Pavlidis N., Terret C., Bauer J., Fiedler W., Schoffski P., Raoul J.L., Hess D., Selvais R., Lacombe D., Bachmann P., and Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur. J. Cancer 39 (2003) 2334-2340
38. Aft R.L., Zhang F.W., and Gius D. Evaluation of 2-deoxy-d-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer 87 (2002) 805-812
39. Brattain M.G., Strobel-Stevens J., Fine D., Webb M., and Sarrif A.M. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40 (1980) 2142-2146
40. Capila I., and Linhardt R.J. Heparin-protein interactions. Angew. Chem., Int. Ed. Engl. 41 (2002) 391-412
41. Casu B. Heparin structure. Haemostasis 20 (1990) 62-73